The Food and Drug Administration has announced its final decision to withdraw approval of Pepaxto, which was approved for use in combination with dexamethasone to treat certain patients with multiple myeloma.

MGMA, the Medical Group Management Association, said it is getting alarming feedback about how physician practices have been impacted by the Change Healthcare cybersecurity attack. Change confirmed today that ALPHV/Blackcat perpetrated the cybercrime.

Bridging the gap between research and clinical practice through digital health technologies is the subject of a HIMSS24 session with the Mayo Clinic’s SaMD regulatory affairs manager, Brenna Loufek.  

In comparison to their traditional Medicare counterparts, Medicare Advantage patients are more likely to experience delays in care (22% vs. 13% for original Medicare). The delays in care for MA patients were largely due to the need to get prior approval, or authorization, according to a Commonwealth Fund survey.

The Justice Department has launched an antitrust investigation into UnitedHealth Group, according to The Wall Street Journal.

Humana has partnered with health technology company Veda to improve the accuracy of its provider information and ensure that seniors have real-time details about in-network providers.

Immediate benefits include helping with healthcare navigation, such as patient check-ins, scheduling appointments and summarizing lab results, says Melek Somai, chief technology and product officer, Froedtert Medical College of Wisconsin Health Network.  

Digital health company Waltz Health, which focuses on technology-enabled ways to price, distribute and prescribe medications, will be entering into the Medicare Advantage arena. The company will offer health plans that support Medicare beneficiaries customizable configurations of its proprietary Marketplace Search technology, which lowers prescription drug prices for members while also providing health plans with […]

The Blackcat ransomware gang is behind the Change Healthcare cybersecurity attack last week that has affected prescription deliveries, according to Reuters.

Settlements and judgments under the False Claims Act exceeded $2.68 billion in the fiscal year ending Sept. 30, 2023, and of that total, more than $1.8 billion related to matters that involved the healthcare industry – including managed care providers, hospitals, pharmacies, laboratories, long-term acute care facilities and physicians.